image
Healthcare - Medical - Devices - NASDAQ - US
$ 8.98
-7.23 %
$ 268 M
Market Cap
-7.95
P/E
1. INTRINSIC VALUE

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.[ Read More ]

The intrinsic value of one NPCE stock under the base case scenario is HIDDEN Compared to the current market price of 8.98 USD, NeuroPace, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NPCE

image
FINANCIALS
65.4 M REVENUE
43.72%
-27.2 M OPERATING INCOME
33.39%
-33 M NET INCOME
30.00%
-19.7 M OPERATING CASH FLOW
46.56%
23 M INVESTING CASH FLOW
-3.24%
8.13 M FINANCING CASH FLOW
1558.57%
21.1 M REVENUE
9.37%
-4.24 M OPERATING INCOME
31.89%
-5.45 M NET INCOME
27.44%
-1.72 M OPERATING CASH FLOW
55.79%
1.4 M INVESTING CASH FLOW
-56.75%
2.9 M FINANCING CASH FLOW
469.35%
Balance Sheet Decomposition NeuroPace, Inc.
image
Current Assets 92.7 M
Cash & Short-Term Investments 66.5 M
Receivables 12.3 M
Other Current Assets 14 M
Non-Current Assets 14.9 M
Long-Term Investments 0
PP&E 14.4 M
Other Non-Current Assets 524 K
Current Liabilities 16.2 M
Accounts Payable 2.33 M
Short-Term Debt 3.25 M
Other Current Liabilities 10.6 M
Non-Current Liabilities 70.8 M
Long-Term Debt 70.8 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall NeuroPace, Inc.
image
Revenue 65.4 M
Cost Of Revenue 17.3 M
Gross Profit 48.1 M
Operating Expenses 75.3 M
Operating Income -27.2 M
Other Expenses 5.78 M
Net Income -33 M
RATIOS
73.56% GROSS MARGIN
73.56%
-41.54% OPERATING MARGIN
-41.54%
-50.38% NET MARGIN
-50.38%
-159.56% ROE
-159.56%
-30.61% ROA
-30.61%
-34.30% ROIC
-34.30%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NeuroPace, Inc.
image
Net Income -33 M
Depreciation & Amortization 1.6 M
Capital Expenditures -173 K
Stock-Based Compensation 9.56 M
Change in Working Capital -2.48 M
Others 8.4 M
Free Cash Flow -19.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NeuroPace, Inc.
image
Wall Street analysts predict an average 1-year price target for NPCE of $18.3 , with forecasts ranging from a low of $15 to a high of $20 .
NPCE Lowest Price Target Wall Street Target
15 USD 67.04%
NPCE Average Price Target Wall Street Target
18.3 USD 104.16%
NPCE Highest Price Target Wall Street Target
20 USD 122.72%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership NeuroPace, Inc.
image
Sold
0-3 MONTHS
1.88 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
8.61 M USD 1
9-12 MONTHS
981 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 weeks ago
Oct 23, 2024
Sell 885 USD
KCK LTD.
10 percent owner
- 147
6.02 USD
3 weeks ago
Oct 25, 2024
Sell 1.22 M USD
KCK LTD.
10 percent owner
- 223991
5.4513 USD
3 weeks ago
Oct 22, 2024
Sell 24.9 K USD
KCK LTD.
10 percent owner
- 4082
6.0885 USD
4 weeks ago
Oct 18, 2024
Sell 30.7 K USD
KCK LTD.
10 percent owner
- 4878
6.2919 USD
3 weeks ago
Oct 21, 2024
Sell 22.7 K USD
KCK LTD.
10 percent owner
- 3720
6.0964 USD
1 month ago
Oct 03, 2024
Sell 23.1 K USD
KCK LTD.
10 percent owner
- 3318
6.9665 USD
1 month ago
Oct 04, 2024
Sell 39.8 K USD
KCK LTD.
10 percent owner
- 5757
6.9185 USD
1 month ago
Oct 07, 2024
Sell 32.7 K USD
KCK LTD.
10 percent owner
- 4910
6.6573 USD
1 month ago
Oct 08, 2024
Sell 38.6 K USD
KCK LTD.
10 percent owner
- 6000
6.4253 USD
1 month ago
Oct 09, 2024
Sell 19.1 K USD
KCK LTD.
10 percent owner
- 3123
6.1048 USD
1 month ago
Oct 10, 2024
Sell 15.3 K USD
KCK LTD.
10 percent owner
- 2504
6.117 USD
1 month ago
Oct 11, 2024
Sell 16.3 K USD
KCK LTD.
10 percent owner
- 2572
6.3451 USD
1 month ago
Oct 14, 2024
Sell 26.4 K USD
KCK LTD.
10 percent owner
- 4031
6.5393 USD
1 month ago
Oct 15, 2024
Sell 26.1 K USD
KCK LTD.
10 percent owner
- 4017
6.497 USD
1 month ago
Oct 16, 2024
Sell 45.3 K USD
KCK LTD.
10 percent owner
- 6900
6.5705 USD
1 month ago
Oct 17, 2024
Sell 20.7 K USD
KCK LTD.
10 percent owner
- 3294
6.28 USD
2 months ago
Aug 30, 2024
Sell 33.5 K USD
KCK LTD.
10 percent owner
- 4314
7.76 USD
2 months ago
Sep 03, 2024
Sell 15.9 K USD
KCK LTD.
10 percent owner
- 2093
7.6 USD
2 months ago
Sep 04, 2024
Sell 105 USD
KCK LTD.
10 percent owner
- 14
7.5 USD
2 months ago
Sep 06, 2024
Sell 82.5 USD
KCK LTD.
10 percent owner
- 11
7.5 USD
2 months ago
Sep 13, 2024
Sell 15.1 K USD
KCK LTD.
10 percent owner
- 1993
7.59 USD
1 month ago
Sep 20, 2024
Sell 5.74 K USD
KCK LTD.
10 percent owner
- 765
7.5 USD
1 month ago
Sep 23, 2024
Sell 2.13 K USD
KCK LTD.
10 percent owner
- 282
7.54 USD
1 month ago
Sep 25, 2024
Sell 38.7 K USD
KCK LTD.
10 percent owner
- 5858
6.6 USD
1 month ago
Sep 26, 2024
Sell 38.5 K USD
KCK LTD.
10 percent owner
- 5821
6.62 USD
1 month ago
Sep 27, 2024
Sell 33.5 K USD
KCK LTD.
10 percent owner
- 5059
6.63 USD
1 month ago
Sep 30, 2024
Sell 32 K USD
KCK LTD.
10 percent owner
- 4749
6.73 USD
1 month ago
Oct 01, 2024
Sell 33.1 K USD
KCK LTD.
10 percent owner
- 4882
6.77 USD
1 month ago
Oct 02, 2024
Sell 26.4 K USD
KCK LTD.
10 percent owner
- 3843
6.87 USD
6 months ago
May 01, 2024
Sell 220 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 15690
14.02 USD
6 months ago
May 02, 2024
Sell 124 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 8842
14.01 USD
6 months ago
May 03, 2024
Sell 65.6 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 4674
14.03 USD
6 months ago
Apr 24, 2024
Sell 25 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 1781
14.06 USD
6 months ago
Apr 19, 2024
Sell 256 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 18253
14.02 USD
6 months ago
Apr 22, 2024
Sell 346 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 24609
14.05 USD
6 months ago
Apr 23, 2024
Sell 311 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 21791
14.29 USD
7 months ago
Apr 16, 2024
Sell 197 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 14069
14.01 USD
7 months ago
Apr 17, 2024
Sell 4.24 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 300
14.15 USD
7 months ago
Apr 18, 2024
Sell 36.9 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 2623
14.06 USD
7 months ago
Apr 11, 2024
Sell 6.69 M USD
ORBIMED ADVISORS LLC
10 percent owner
- 461899
14.49 USD
7 months ago
Apr 12, 2024
Sell 333 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 23101
14.42 USD
9 months ago
Feb 02, 2024
Sell 213 K USD
Morrell Martha
Chief Medical Officer
- 14143
15.0691 USD
9 months ago
Feb 05, 2024
Sell 52.3 K USD
Morrell Martha
Chief Medical Officer
- 3446
15.1707 USD
9 months ago
Jan 30, 2024
Sell 170 K USD
Morrell Martha
Chief Medical Officer
- 11262
15.0954 USD
9 months ago
Jan 31, 2024
Sell 29 K USD
Morrell Martha
Chief Medical Officer
- 1923
15.0752 USD
9 months ago
Feb 01, 2024
Sell 9.97 K USD
Morrell Martha
Chief Medical Officer
- 663
15.0393 USD
9 months ago
Jan 24, 2024
Sell 12.4 K USD
Morrell Martha
Chief Medical Officer
- 827
15.025 USD
9 months ago
Jan 25, 2024
Sell 15 USD
Morrell Martha
Chief Medical Officer
- 1
15 USD
10 months ago
Dec 26, 2023
Sell 1.02 K USD
Morrell Martha
Chief Medical Officer
- 102
10 USD
10 months ago
Dec 27, 2023
Sell 135 K USD
Morrell Martha
Chief Medical Officer
- 13300
10.1239 USD
10 months ago
Dec 20, 2023
Sell 27.7 K USD
Morrell Martha
Chief Medical Officer
- 2730
10.1448 USD
11 months ago
Dec 06, 2023
Sell 89.8 K USD
Morrell Martha
Chief Medical Officer
- 11005
8.1575 USD
11 months ago
Nov 29, 2023
Sell 49.2 K USD
KCK LTD.
10 percent owner
- 5644
8.72 USD
11 months ago
Nov 30, 2023
Sell 64.4 K USD
KCK LTD.
10 percent owner
- 7282
8.84 USD
11 months ago
Dec 01, 2023
Sell 28.3 K USD
KCK LTD.
10 percent owner
- 3241
8.73 USD
11 months ago
Nov 27, 2023
Sell 58.2 K USD
KCK LTD.
10 percent owner
- 6490
8.96 USD
11 months ago
Nov 28, 2023
Sell 41 K USD
KCK LTD.
10 percent owner
- 4681
8.75 USD
1 year ago
Oct 02, 2023
Sell 69.1 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 7614
9.08 USD
1 year ago
Oct 03, 2023
Sell 6.31 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 700
9.02 USD
1 year ago
Nov 22, 2022
Bought 93.5 K USD
Accelmed Partners II L.P.
Director
+ 62398
1.499 USD
1 year ago
Nov 21, 2022
Bought 492 K USD
Accelmed Partners II L.P.
Director
+ 327893
1.499 USD
2 years ago
Jun 08, 2022
Sell 14.4 K USD
Ridley Irina
General Counsel and Secretary
- 2500
5.778 USD
2 years ago
Feb 28, 2022
Sell 11.1 K USD
Ridley Irina
General Counsel and Secretary
- 1470
7.5386 USD
3 years ago
Apr 21, 2021
Bought 4 M USD
ORBIMED ADVISORS LLC
10 percent owner
+ 235000
17 USD
3 years ago
Apr 21, 2021
Bought 40 K USD
Ridley Irina
General Counsel and Secretary
+ 2352
17 USD
3 years ago
Apr 21, 2021
Bought 10 M USD
Accelmed Partners II L.P.
10 percent owner
+ 588235
17 USD
3 years ago
Apr 21, 2021
Bought 850 K USD
Fischer Frank M
Director
+ 50000
17 USD
3 years ago
Apr 21, 2021
Bought 225 K USD
Garfield Greg Shaw
Director
+ 13235
17 USD
3 years ago
Apr 21, 2021
Bought 10 M USD
Norton Evan
Director
+ 588235
17 USD
7. News
NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Mike Kratky – Leerink Partners Vik Chopra – Wells Fargo Ross Osborn – Cantor Fitzgerald Michael Polark – Wolfe Research Operator Greetings and welcome to NeuroPace's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 4 days ago
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago. zacks.com - 4 days ago
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug - resistant focal epilepsy globenewswire.com - 1 week ago
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 2 weeks ago
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024 MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com - 3 weeks ago
NeuroPace Continues to Strengthen Management Team Appoints experienced people leader as Vice President of Human Resources Appoints experienced people leader as Vice President of Human Resources globenewswire.com - 1 month ago
NeuroPace Strengthens Management Team with Two Key Appointments Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. globenewswire.com - 2 months ago
NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in the following two healthcare investor conferences in September. globenewswire.com - 2 months ago
NeuroPace to Participate in Upcoming Healthcare Conferences in September MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA. globenewswire.com - 2 months ago
NeuroPace: Only For Those With Strong Nerves NeuroPace, Inc. aims to improve the lives of epilepsy patients with RNS technology, addressing drug-resistant epilepsy. The company has seen revenue growth, but continues to post losses nonetheless. NeuroPace stock is displaying substantial volatility and looks interesting on a highly speculative basis, anticipating wider approval of RNS. seekingalpha.com - 2 months ago
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter. zacks.com - 2 months ago
NeuroPace, Inc. (NPCE) Q2 2024 Earnings Call Transcript NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Ross Osborn - Cantor Fitzgerald Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Robert Marcus - JP Morgan Michael Polark - Wolfe Research Operator Good afternoon and welcome to NeuroPace's Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. seekingalpha.com - 3 months ago
8. Profile Summary

NeuroPace, Inc. NPCE

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 268 M
Dividend Yield 0.00%
Description NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Contact 455 North Bernardo Avenue, Mountain View, CA, 94043 https://www.neuropace.com
IPO Date April 22, 2021
Employees 184
Officers Ms. Amy Treadwell Vice President of Human Resources Ms. Kelley Nicholas Vice President of Sales Mr. Joel D. Becker Chief Executive Officer, President & Director Ms. Leah Akin Acting General Counsel Ms. Rebecca L. Kuhn Chief Financial Officer, Vice President of Finance & Administration, Corporate Secretary and Assistant Secretary Dr. Martha J. Morrell Chief Medical Officer Mr. Dylan St. John Chief of Operations & Development